ClinicalTrials.gov registry snapshot / 2026-07-24

Peptide trials,
without the maze.

Search every official registry record matched to 13 tracked peptide and next-generation weight-loss programs. Find current status, phase, enrollment, countries, US states, recruiting cities, postal areas, completion timing, and the direct NCT source.

268unique NCT records
13named programs
53countries represented
1,840recruiting cities
11registry result modules
Recruiting footprint by program

Study status is not drug rank.

Bar length shows registry-listed sites individually marked Recruiting. Larger programs can create larger counts. This does not compare efficacy, safety, approval odds, sponsor quality, or enrollment availability.

Official registry finder

Filter the exact records.

Search names, former codes, NCT IDs, sponsors, interventions, conditions, cities, and postal codes. Filtered URLs are shareable but intentionally excluded from search indexing so this page remains the canonical source.

Reset
10matching registry records
Matching recruiting site observations5
Program and recordStatusPhase and enrollmentLocationsPrimary completionRegistry updateSource
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)NCT07165028 / Eli Lilly and CompanyRecruitingVerified 2026-07Phase 34,500 estimated5 matching recruitingChicoutimi, G7H 7K9, Canada / North Bay, P1B 2H3, Canada / Québec, G1V 4T3, Canada / 2 more areasAug 2030estimatedJul 17, 2026ClinicalTrials.govOpen NCT07165028
A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular DiseaseNCT05882045 / TRIUMPH-3 / Eli Lilly and CompanyActive, not recruitingVerified 2026-05Phase 31,946 actual0 matching recruitingNo city or postal detail is present for the matching registry rows.Apr 16, 2026actualMay 22, 2026ClinicalTrials.govOpen NCT05882045
Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)NCT06260722 / Eli Lilly and CompanyActive, not recruitingVerified 2026-04Phase 31,250 estimated0 matching recruitingNo city or postal detail is present for the matching registry rows.Aug 2026estimatedApr 13, 2026ClinicalTrials.govOpen NCT06260722
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)NCT06383390 / Eli Lilly and CompanyActive, not recruitingVerified 2026-07Phase 310,000 estimated0 matching recruitingNo city or postal detail is present for the matching registry rows.Feb 2029estimatedJul 20, 2026ClinicalTrials.govOpen NCT06383390
A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With ObesityNCT06859268 / TRIUMPH-6 / Eli Lilly and CompanyActive, not recruitingVerified 2026-02Phase 3643 estimated0 matching recruitingNo city or postal detail is present for the matching registry rows.Apr 2028estimatedMar 3, 2026ClinicalTrials.govOpen NCT06859268
A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back PainNCT07035093 / TRIUMPH-7 / Eli Lilly and CompanyActive, not recruitingVerified 2026-07Phase 3586 estimated0 matching recruitingNo city or postal detail is present for the matching registry rows.Sep 2027estimatedJul 23, 2026ClinicalTrials.govOpen NCT07035093
A Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or OverweightNCT07357415 / TRIUMPH-9 / Eli Lilly and CompanyActive, not recruitingVerified 2026-06Phase 3600 estimated0 matching recruitingNo city or postal detail is present for the matching registry rows.Oct 2028estimatedJun 9, 2026ClinicalTrials.govOpen NCT07357415
A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or OverweightNCT05929066 / TRIUMPH-1 / Eli Lilly and CompanyCompletedVerified 2026-06Phase 32,335 actual0 matching recruitingNo city or postal detail is present for the matching registry rows.Apr 6, 2026actualJun 3, 2026ClinicalTrials.govOpen NCT05929066
A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the KneeNCT05931367 / TRIUMPH-4 / Eli Lilly and CompanyCompletedVerified 2026-01Phase 3445 actual0 matching recruitingNo city or postal detail is present for the matching registry rows.Nov 14, 2025actualJan 21, 2026ClinicalTrials.govOpen NCT05931367
A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 DiabetesNCT05936151 / Eli Lilly and CompanyCompletedVerified 2025-11Phase 2146 actual0 matching recruitingNo city or postal detail is present for the matching registry rows.Oct 1, 2025actualNov 25, 2025ClinicalTrials.govOpen NCT05936151
Clinical trial finder FAQ

Status, location, and enrollment are different fields.

These answers prevent the most common registry-search errors before a reader follows an official source.

01

Are any Retatrutide clinical trials recruiting?

Yes. This 2026-07-24 snapshot contains 2 Retatrutide registry records with an overall Recruiting status and 450 listed sites individually marked Recruiting. Overall status does not mean every site is open, and neither status establishes eligibility or enrollment. Open the exact NCT record and verify the individual location before contacting a study team.

02

How do I find a peptide clinical trial near me?

Enter a city or postal code, optionally add a country or US state, and then open the exact ClinicalTrials.gov record. This finder retains location rows individually marked Recruiting but omits facility and personal contact fields. Confirm current recruitment, eligibility, official contact route, and travel requirements on the registry. Peptide Local does not enroll participants.

03

Does Recruiting mean I can join the trial?

No. Recruiting is a registry status, not an eligibility decision or appointment. A study can be recruiting overall while some listed locations are not yet recruiting, active but closed, completed, suspended, or missing a current site status. The study team applies the protocol's eligibility and consent process.

04

Are the drugs in this clinical trial finder FDA approved?

A ClinicalTrials.gov record is not FDA approval. The finder covers investigational programs and can also include studies involving components or comparators with separate regulatory histories. Approval must be verified on the exact FDA label or regulator record, not inferred from a phase, sponsor, trial result, or recruiting status.

05

Why do only some registry records show posted results?

11 of 268 records in this snapshot expose a ClinicalTrials.gov results module. A record without posted registry results can still have a publication or sponsor announcement elsewhere, while a posted module still requires careful interpretation. Results availability is not a quality rank.

06

How current is the peptide clinical trial data?

The registry data timestamp is July 24, 2026 at 9:00 AM UTC. The refresh workflow searches exact intervention names and aliases, deduplicates by NCT ID, preserves multi-program studies, and stores overall and individual-site status separately. Registry fields can change after that timestamp, so the direct source remains authoritative for enrollment decisions.

Evidence boundary

A registry finder, not an enrollment service.

A dated transformation of ClinicalTrials.gov intervention-search records for thirteen named Peptide Local pipeline programs. Study sponsors or investigators submit and maintain registry records. Overall status, individual-site status, enrollment, locations, completion dates, and results availability can change. Recruiting status does not establish eligibility, enrollment, treatment access, regulatory approval, routine availability, or a favorable benefit-risk conclusion.

Peptide Local omits personal contact details and does not screen participants, recommend a protocol, interpret eligibility, arrange treatment, or authenticate commercial products that reuse an investigational program's name.

Read the official API documentation ↗Understand evidence categories →